share_log

Chardan Capital Maintains Sell on Mesoblast, Lowers Price Target to $1.5

Benzinga ·  Aug 4, 2023 06:37

Chardan Capital analyst Keay Nakae maintains Mesoblast (NASDAQ:MESO) with a Sell and lowers the price target from $2 to $1.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment